Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424910 | 0.90 | FAAH (0.57) | FAAHCES2CLK1DYRK1ACHUK | |
| SCHEMBL7899710 | 0.88 | FAAH (0.48) | FAAHCES2TGFBR1PIK3CDHSD11B1 | |
| SCHEMBL427883 | 0.86 | FAAH (0.48) | FAAHCES2TGFBR1MAPK1PIK3CD | |
| SCHEMBL427732 | 0.85 | FAAH (0.53) | FAAHCES2TGFBR1HSD11B1 | |
| SCHEMBL425023 | 0.84 | DRD3 (0.43) | FAAHCES2CLK1DYRK1ACHUK | |
| SCHEMBL424911 | 0.84 | FAAH (0.48) | FAAHCES2TGFBR1PIK3CD | |
| SCHEMBL427419 | 0.83 | FAAH (0.48) | FAAHCES2TGFBR1MAPK1PIK3CD | |
| SCHEMBL14950261 | 0.83 | FAAH (0.53) | FAAHCES2TGFBR1HSD11B1 | |
| SCHEMBL427361 | 0.82 | FAAH (0.52) | FAAHCES2TGFBR1 | |
| SCHEMBL427871 | 0.82 | FAAH (0.52) | FAAHCES2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885CLK1 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.